Kyverna Therapeutics (Kyverna Therapeutics) Total Liabilities : $28.99 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Total Liabilities?

Kyverna Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $28.99 Mil.

Kyverna Therapeutics's quarterly Total Liabilities increased from Sep. 2023 ($204.29 Mil) to Dec. 2023 ($206.59 Mil) but then declined from Dec. 2023 ($206.59 Mil) to Mar. 2024 ($28.99 Mil).

Kyverna Therapeutics's annual Total Liabilities increased from Dec. 2021 ($131.74 Mil) to Dec. 2022 ($140.92 Mil) and increased from Dec. 2022 ($140.92 Mil) to Dec. 2023 ($206.59 Mil).

Kyverna Therapeutics Total Liabilities Historical Data

The historical data trend for Kyverna Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Total Liabilities Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Total Liabilities

131.74

140.92

206.59

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial			140.92	-	204.29	206.59	28.99

Kyverna Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kyverna Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	19.859	+	(6.159	+	180.574
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	206.59

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	75.195	-	-131.397
	=	206.59

Kyverna Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	21.865	+	(7.128	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	28.99

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	389.984	-	360.991
	=	28.99

Kyverna Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024